a). Amendment to the Claims

Claims 1-15 (Cancelled)

pharmaceutically acceptable carrier and an indolocarbazole derivative, said

pharmaceutically acceptable carrier and said indolocarbazole derivative being

encapsulated in a liposome with an average particle size of 120 to 500 nm, said liposome

consisting of lipid(s) selected from the group consisting of (i) hydrogenated soybean

phosphatidylcholine and (ii) mixed lipids of hydrogenated soybean phosphatidylcholine

and polyethylene glycol-modified phospholipid.

Claims 17-18 (Cancelled).

- 19. (Previously Presented) The pharmaceutical composition according to claim 16, wherein the lipids are mixed lipids of hydrogenated soybean phosphatidylcholine and polyethylene glycol-modified phospholipid.
- 20. (Previously Presented) The pharmaceutical composition according to claim 16, wherein the lipids are hydrogenated soybean phosphatidylcholine.

Claims 21-34 (Cancelled).

35. (Previously Presented) The pharmaceutical composition according to any one of claims 16, 19 or 20, wherein said liposome comprises at least two bilayers of said lipid(s).

Claims 36-41 (Cancelled)

- 42. (Currently Amended) A liposome preparation encapsulating an indolocarbazole indolocarbazole derivative, comprising liposomes with encapsulating an indolocarbazole derivative, said liposome having an average particle size of 120 nm to 500 nm, wherein the liposomes eonsists consist of lipid(s) selected from the group consisting of (i) hydrogenated soybean phosphatidylcholine and (ii) mixed lipids of hydrogenated soybean phosphatidylcholine and polyethylene glycol-modified phospholipid.
- 43. (Previously Presented) The liposome preparation according to claim 42, wherein the lipids are mixed hydrogenated soybean phosphatidylcholine and polyethylene glycol-modified phospholipid.
- 44. (Previously Presented) The liposome preparation according to claim 42, wherein the lipid is hydrogenated soybean phosphatidylcholine.

Claims 45-48 (Cancelled).